200 Technology Square
About Moderna, Inc.
Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. Moderna’s platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing the Company the capability to pursue in parallel a robust pipeline of new development candidates. Moderna is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and cardiovascular diseases, independently and with strategic collaborators.
mRNA is now a turning point in the history of science, medicine, technology, even humankind itself. With this breakthrough discovery, many of the world’s biggest and most challenging medical problems are no longer a question of “how?” but merely a question of “when?”
Come with us as we pursue the uncharted reaches of possibility and make your mark on the future of medicine.
Moderna employees share their thoughts on our culture, values and mission. To hear additional employee stories and learn more about our inclusive and innovative benefits offerings, visit us on our website.
1031 articles with Moderna, Inc.
Now that most people in North America and Europe are vaccinated and the COVID-19 pandemic is diminishing, Moderna is looking for its second act.
Ministry Of Health, Labour and Welfare in Japan Approves Partial Change to a New Drug Authorization for Moderna's Omicron-Targeting Bivalent Booster COVID-19 Vaccine, mRNA-1273.214
Moderna, Inc. today announced that it has received approval from the Ministry of Health, Labour and Welfare (MHLW) in Japan for a partial change to a new drug application for its Omicron-targeting bivalent COVID-19 booster, mRNA-1273.214 (Spikevax Bivalent Original/Omicron BA.1).
Moderna is preparing for multiple product launches over the next several years, including RSV and flu vaccines and boosters for COVID-19. It is also aiming mRNA programs at rare diseases.
Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, announced advances across its portfolio of mRNA programs presented at the Company's annual R&D Day.
Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, announced that Stephen Hoge, M.D., President, will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, September 13th at 10:00 a.m. ET.
The U.S. Food and Drug Administration had a busy week leading up to the Labor Day holiday. Here’s a look at the agency’s recent activities.
On Wednesday, the FDA authorized new Omicron-specific booster shots for Pfizer-BioNTech and Moderna’s COVID-19 vaccines despite a lack of human data.
Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, announced that Health Canada has authorized the use of its Omicron-targeting bivalent COVID-19 booster vaccine, mRNA-1273.214 as a booster dose for active immunization against COVID-19 caused by the SARS-CoV-2 virus in individuals 18 years of age and older.
EMA Committee for Medicinal Products for Human Use (CHMP) Adopts Positive Opinion Recommending Authorization for the Use of Moderna's Omicron-Targeting Bivalent Booster in the European Union
Moderna, Inc. announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion recommending conditional marketing authorization for Spikevax bivalent Original/Omicron BA.1, the company's next-generation bivalent vaccine candidate that contains mRNA-1273 and a vaccine candidate targeting the Omicron variant of concern.
Moderna Receives FDA Authorization for Emergency Use of Omicron-Targeting Bivalent COVID-19 Booster Vaccine for Adults 18 Years and Older
Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, announced that it has received emergency use authorization from the U.S. Food and Drug Administration for its BA.4/.5 Omicron-targeting bivalent COVID-19 booster vaccine, mRNA-1273.222.
Therapeutic Goods Administration Provisionally Approves Moderna’s Omicron-Containing Bivalent Booster Candidate, MRNA-1273.214, For Australia
Moderna, Inc. announced that the Therapeutic Goods Administration in Australia has granted provisional approval for its Omicron-containing bivalent booster vaccine, mRNA-1273.214 as a booster dose for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older.
Moderna, Inc. announced that Swissmedic has granted temporary authorization for the use of Moderna's Omicron-targeting bivalent booster vaccine, Spikevax Bivalent Original/Omicron for active immunization to prevent SARS-CoV-2 virus-induced Coronavirus-2019 disease for individuals aged 18 years and older.
Moderna, Inc today announced it will host its in-person and virtual R&D Day at 9:00 a.m. ET on Thursday, September 8, 2022.
Moderna announced it is filing lawsuits against Pfizer and BioNTech, alleging that the companies’ COVID-19 vaccine infringes patents covering its mRNA technology.
Moderna Sues Pfizer and BioNTech for Infringing Patents Central to Moderna's Innovative mRNA Technology Platform
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today is filing patent infringement lawsuits against Pfizer and BioNTech in the United States District Court for the District of Massachusetts and the Regional Court of Düsseldorf in Germany.
A day after Pfizer and partner BioNTech submitted an EUA request to the FDA for their booster shot targeting Omicron variants BA.4 and BA.5, the regulator appears close to approving it.
Moderna Completes Application To U.S. Food And Drug Administration For Emergency Use Authorization Of Omicron-Targeting Bivalent Covid-19 Booster Vaccine, mRNA-1273.222
Moderna, Inc. announced that it has completed its submission to the U.S. Food and Drug Administration for emergency use authorization for its BA.4/BA.5 Omicron-targeting bivalent COVID-19 booster vaccine, mRNA-1273.222.
Moderna to Supply 12 Million Doses of Omicron-Containing Bivalent COVID-19 Booster Vaccines to the Government of Canada
Moderna, Inc. today announced that the Government of Canada has exercised its option to purchase an additional 4.5 million doses of an Omicron-containing bivalent vaccine booster.
Moderna, Inc. today announced that James Mock has been appointed as Moderna's Chief Financial Officer, beginning September 6, 2022.
The U.K's MHRA has granted conditional authorization to Moderna's newest vaccine candidate, making it the first Omicron-specific COVID-19 booster vaccine approved by a regulatory agency.